Strides Arcolab shares slump as investors cast doubt on asset sale report
MUMBAI (Reuters) - Strides Arcolab Ltd (STAR.NS) slumped as much as 17.4 percent in Mumbai trading on Thursday as investors cast doubt on media reports that the drug maker may sell its injectable-medicines unit Agila Specialties.
Bloomberg News and the local media said last month that Strides was in talks to sell Agila to Pfizer Inc PFE.NS. Pfizer is doing due diligence and a deal could be reached this quarter, Bloomberg said, citing sources that it did not identify.
"There is market talk the deal with Pfizer might get delayed or cancelled," said Narayan Patra, an analyst at Systematix.
A spokesman at Strides declined to comment, while officials at Pfizer could not be immediately reached.
Shares in Striders were down 11.2 percent as of 0633 GMT.
(Reporting by Abhishek Vishnoi; Writing by Rafael Nam; Editing by Ryan Woo)
- Tweet this
- Share this
- Digg this
- India passes halfway mark in election with BJP gaining strength
- UPDATE 2-Chipotle raising prices as steak, avocados, cheese costs rise
- Scientists find Earth-sized world in orbit friendly to life
- UPDATE 8-Divers struggle in search for South Korean ferry survivors
- 'X-Men' director Bryan Singer accused of drugging, raping teen
Wipro posted a 29 percent rise in its fourth-quarter net profit, beating expectations, helped by increased IT spending by its customers. For the quarter ended March 31, the company said it earned 22.27 billion rupees compared with 17.29 billion rupees a year earlier. Full Article | Full Coverage
Ex-Goldman director Rajat Gupta to surrender June 17 in insider case. Full Article